On February 15, 2021, Hascup, Kevin N.; Findley, Caleigh A.; Britz, Jesse; Esperant-Hilaire, Nahayo; Broderick, Sarah O.; Delfino, Kristin; Tischkau, Shelley; Bartke, Andrzej; Hascup, Erin R. published an article.Name: 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate The title of the article was Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice. And the article contained the following:
We have previously demonstrated hippocampal hyperglutamatergic signaling occurs prior to plaque accumulation in AβPP/PS1 mice. Here, we evaluate 2-Amino-6-(trifluoromethoxy) benzothiazole (riluzole) as an early intervention strategy for Alzheimers disease (AD), aimed at restoring glutamate neurotransmission prior to substantial Beta amyloid (Aβ) plaque accumulation and cognitive decline. Male AβPP/PS1 mice, a model of progressive cerebral amyloidosis, were treated with riluzole from 2-6 mo of age. Morris water maze, in vivo electrochem., and immunofluorescence were performed to assess cognition, glutamatergic neurotransmission, and pathol., resp., at 12 mo. Four months of prodromal riluzole treatment in AβPP/PS1 mice resulted in long-lasting procognitive effects and attenuated glutamatergic tone that was observed six months after discontinuing riluzole treatment. Riluzole-treated AβPP/PS1 mice had significant improvement in long-term memory compared to vehicle-treated AβPP/PS1 mice that was similar to normal aging C57BL/6J control mice. Furthermore, basal glutamate concentration and evoked-glutamate release levels, which were elevated in vehicle-treated AβPP/PS1 mice, were restored to levels observed in age-matched C57BL/6J mice in AβPP/PS1 mice receiving prodromal riluzole treatment. Aβ plaque accumulation was not altered with riluzole treatment. This study supports that interventions targeting the glutamatergic system during the early stages of AD progression have long-term effects on disease outcome, and importantly may prevent cognitive decline. Our observations provide preclin. support for targeting glutamate neurotransmission in patients at risk for developing AD. The experimental process involved the reaction of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate(cas: 6197-30-4).Name: 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate
The Article related to riluzole nmda receptor glutamatergic tone ps1 alzheimers disease, alzheimer’s disease (ad), alpha-7 nicotinic acetylcholine receptor (α7nachr), amyloid-beta (aβ), biosensor, learning and memory, prodromal intervention and other aspects.Name: 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics